Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?

IF 5.7 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Atherosclerosis Reports Pub Date : 2023-12-01 Epub Date: 2023-12-04 DOI:10.1007/s11883-023-01166-3

Hana Poloczková, Jan Krejčí

{"title":"Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?","authors":"Hana Poloczková, Jan Krejčí","doi":"10.1007/s11883-023-01166-3","DOIUrl":null,"url":null,"abstract":"Purpose of review: An evidence for lipid lowering therapy in heart failure is briefly summarized in this review.Recent findings: Heart failure therapy is based on recent guidelines for diagnosis and treatment of acute and chronic heart failure. The question of the importance of hypolipidemic treatment in heart failure remains insufficiently answered. We still rely only on results of two randomized controlled trials that did not show significant benefit of statins on mortality in these patients. In contrast, some meta-analysis, prospective or retrospective cohorts, found some positive effects of this therapy. Recently, the role of inflammation and the possibility of its influence by hypolipidemics have been discussed. PCSK9 inhibitors, new lipid lowering drugs, are very effective in LDL-cholesterol lowering and atherosclerotic cardiovascular diseases prevention. The role of PCSK9 inhibitors in heart failure treatment is investigated. Based on current knowledge, hypolipidemics are not generally recommended in heart failure therapy, unless there is another indication for their use.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"957-964"},"PeriodicalIF":5.7000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Atherosclerosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11883-023-01166-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: An evidence for lipid lowering therapy in heart failure is briefly summarized in this review.

Recent findings: Heart failure therapy is based on recent guidelines for diagnosis and treatment of acute and chronic heart failure. The question of the importance of hypolipidemic treatment in heart failure remains insufficiently answered. We still rely only on results of two randomized controlled trials that did not show significant benefit of statins on mortality in these patients. In contrast, some meta-analysis, prospective or retrospective cohorts, found some positive effects of this therapy. Recently, the role of inflammation and the possibility of its influence by hypolipidemics have been discussed. PCSK9 inhibitors, new lipid lowering drugs, are very effective in LDL-cholesterol lowering and atherosclerotic cardiovascular diseases prevention. The role of PCSK9 inhibitors in heart failure treatment is investigated. Based on current knowledge, hypolipidemics are not generally recommended in heart failure therapy, unless there is another indication for their use.

查看原文本刊更多论文

2023年心力衰竭治疗:降脂治疗有一席之地吗?

综述目的:本文简要总结了降脂治疗心力衰竭的证据。最近的发现:心力衰竭的治疗是基于急性和慢性心力衰竭的诊断和治疗的最新指南。低血糖治疗在心力衰竭中的重要性问题仍然没有得到充分的回答。我们仍然只依赖于两项随机对照试验的结果，这些试验没有显示他汀类药物对这些患者的死亡率有显著的益处。相比之下，一些荟萃分析，前瞻性或回顾性队列，发现了这种治疗的一些积极作用。最近，人们讨论了炎症的作用及其受低血脂影响的可能性。PCSK9抑制剂是一种新型降脂药物，在降低低密度脂蛋白胆固醇和预防动脉粥样硬化性心血管疾病方面非常有效。研究了PCSK9抑制剂在心力衰竭治疗中的作用。根据目前的知识，一般不建议在心力衰竭治疗中使用低血脂，除非有其他适应症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Atherosclerosis Reports 医学-

CiteScore

9.00

自引率

3.40%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of this journal is to systematically provide expert views on current basic science and clinical advances in the field of atherosclerosis and highlight the most important developments likely to transform the field of cardiovascular prevention, diagnosis, and treatment. We accomplish this aim by appointing major authorities to serve as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and papers published in the past year. We also provide supplementary reviews and commentaries from well-known figures in the field. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.